Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CurcuSYM is a natural product formulation developed by Symbion Life Science, a pharmaceutical company based in Gujarat, India, specializing in oncology and supportive care. The product is a combination of two patented extracts: BCM-95, a 95% purified turmeric extract containing 500 mg of curcuminoids per serving, and BioPerine, a 95% piperine extract (10 mg per serving) derived from black pepper. The primary rationale for this combination is to address the poor systemic bioavailability of curcumin; piperine acts as a bioenhancer by inhibiting metabolic pathways such as glucuronidation in the liver and intestinal wall, thereby significantly increasing curcumin absorption. CurcuSYM is marketed for its anti-inflammatory, antioxidant, and potential anti-cancer properties, and is categorized as an anti-cancer supportive care product. It is available as vegetarian capsules and, according to manufacturer information, requires a prescription for use in clinical supportive care settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CurcuSYM.